Thromboxane A(2) (TXA(2)) has recently become a target of intense research because of its myriad of potent pathophysiological properties. Recent progress in TXA(2) research is reviewed in relation to: (1) characterisation of TXA, receptors in platelets and vasculature by kinetic analysis, with evidence for the presence of distinctive receptor subtypes; (2) actions of TXA(2) in platelets and vasculature via their own receptors, i.e. biochemical mechanisms of signal transduction; and (3) pathophysiological roles of TXA(2) and clinical perspectives of TXA(2) blocking therapy.
No takes yet. Share an insight, caveat, or question.
Hanasaki et al. (1991) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: